CEO David Hallal shared with CNBC how ElevateBio is disrupting the industry by offering partners an integrated tech stack with end-to-end manufacturing through its genetic medicine foundry model. Watch his full interview at https://lnkd.in/eACRdDps.
ElevateBio
Biotechnology Research
Waltham, Massachusetts 33,813 followers
A cell and gene therapy company accelerating access to technologies and expertise to change the future of medicine.
Über uns
ElevateBio is a technology-driven company built to power transformative genetic medicines today and for many decades to come. The Company commercializes its enabling technologies, manufacturing capabilities, and industry-leading expertise through partnerships to accelerate development across a breadth of therapeutic approaches and modalities. The ElevateBio ecosystem combines multiple R&D technology platforms – including Life Edit, a next-generation, full-spectrum gene editing platform; comprehensive cell engineering technologies; and an expanded viral and non-viral therapeutic delivery platform – with BaseCamp®, its end-to-end genetic medicine cGMP manufacturing and process development business, to accelerate the discovery and development of advanced therapeutics. ElevateBio aims to be the dominant engine inside the world’s greatest scientific advancements harnessing human cells and genes to alter disease.
- Website
-
https://www.elevate.bio/
External link for ElevateBio
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 201-500 Mitarbeiter
- Hauptsitz
- Waltham, Massachusetts
- Typ
- In Privatbesitz
- Spezialitäten
- cell therapy, gene therapy, and cell and gene therapy
Standorte
-
Primäre
200 Smith St
Waltham, Massachusetts 02451, US
Employees at ElevateBio
Aktualisierungen
-
Our enabling technologies includes a full-spectrum gene editing platform, comprehensive cell therapy enabling technologies, an RNA engineering platform, and viral and non-viral therapeutic delivery platforms. Learn more here: https://lnkd.in/g8hSrXpA.
-
We'll be presenting at the CAR-TCR Summit! Join Katie Jorgensen, VP, Site Head, BaseCamp, for "Blueprints for Success: Building a Cutting-Edge Cell Therapy Facility" and "From Clinical Success to Commercial Readiness: Mastering the Transition in Cell Therapy Manufacturing," on the Late-Stage Manufacturing Track on Sept 18. See you there!
-
Through our partnership with Kyverna Therapeutics, we are advancing process development and manufacturing to produce industry-leading Ingenui-T-derived chimeric antigen receptor (CAR) T-cell therapies. Learn more about our partnership: https://lnkd.in/djqK2qjV. #ElevateBio #CellAndGeneTherapy #Partnership
-
Join our culture of expedition and climb to new heights with us. If you have a passion for discovering and developing life-transforming therapies, you sound like a perfect fit for ElevateBio. To learn more about career opportunities, visit: elevate.bio/about/careers/.
-
We're pushing boundaries when it comes to artificial intelligence (AI). CRISPR, a gene editing tool, is revolutionizing the therapeutic landscape with the promise of curing diseases. With its vast potential, AI is becoming an essential component in the future of gene editing, shaping the development of novel and life-changing genetic medicines. See how Life Edit is rewriting the future of medicine with the power of AI in our latest Elevated Insights– read it here: https://bit.ly/3XAp2cX
-
Today, members of our team joined the University of Pittsburgh and state and local leaders at a ceremonial beam signing event at the new BaseCamp Pittsburgh biomanufacturing facility. This collaborative effort is set to create 170+ full-time positions and an additional 900 jobs as construction progresses. The BaseCamp facility will serve as a cornerstone for scientific innovation, advancing transformative medicines for patients. "This partnership between ElevateBio and the University of Pittsburgh is more than just a collaboration; it’s a shared vision to advance the future of medicine and manufacturing." - Vikas Sinha, Chief Financial Officer, ElevateBio. We are proud to mark this impactful milestone in Pittsburgh, driving forward a new era of biomedical innovation to enhance the future of medicine and healthcare.
-
We've identified over 2.1M+ CRISPR-Cas systems and are advancing our protein discovery to create #GeneEditing therapies for a wide array of challenging disorders. Explore our cutting-edge genome editing platform at lifeeditinc.com. #CRISPRCasSystems #GenomeEditing
-
Join us at BioCentury's Grand Rounds 2024!
We'll be attending BioCentury's Grand Rounds 2024! Join Clare Murray, Ph.D, SVP, Corporate Development & Operations, for the panel discussion “Maximizing the impact of gene editing: Incremental improvements or leaps to newer technologies?” Learn about the conference at https://lnkd.in/gakuvuEn.
-
Process characterization is essential to how we support our partners' product development. Our team works closely to gain a well-understanding of key performance parameters and define effective process control strategies. Our in-house analytical methods enable us to achieve the right product profile in every step of the development process. From concept to commercialization, we are here to support you at any stage. #ElevateBio #CellAndGeneTherapy